This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
COL5A3 / Collagen alpha-3(V) chain · IHC design guide
Design Immunohistochemistry for COL5A3
Plan chromogenic COL5A3 IHC on paraffin sections using the observed cytoplasmic tissue pattern and the extracellular matrix location as separate expectations (HPA tissue IHC; UniProt). High staining in cervix squamous epithelial cells provides a reference, and the catalog antibody's 1:100–1:300 IHC dilution provides a starting range (HPA tissue IHC; datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
COL5A3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); extracellular matrix expected (UniProt) | |
| Staining pattern | Cytoplasmic staining in squamous, glandular and Leydig cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Cervix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A10525) | |
| Caveat | Secreted protein; tissue staining may diverge from RNA (HPA tissue IHC) | |
| Regulation | Regulation not specified (UniProt) | |
| Isoform / epitope | No isoforms; signal 1–29 is removed; no cytoplasmic epitope (UniProt) |
Section 1
Recommended COL5A3 IHC & IF Protocols
The catalog antibody protocol is accompanied by one published COL5A3 IHC protocol for clear cell renal cell carcinoma (PMC10891384).
| Sample | Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A10525) |
| Fixation | Image fixative and duration unreported (datasheet A10525); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-COL5A3, 1:100-1:300 (datasheet A10525) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | COL5A3-positive staining in squamous epithelial cells of cervix (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page antigen retrieval); the published protocol uses microwave retrieval for 25 min (PMC10891384).
Section 2
What Is the Expected COL5A3 Staining Pattern?
COL5A3 is secreted and assigned to the extracellular matrix, with no transmembrane segment (UniProt P25940 localization and topology). In tissue IHC, HPA reports general cytoplasmic expression, including high staining in cervical and tonsillar squamous epithelial cells, intestinal and parathyroid glandular cells, and testicular Leydig cells (HPA: tissue IHC). Its IHC reliability is Approved, with low agreement between staining and RNA data and external verification pending (HPA: reliability).
| Strong cytoplasmic staining in cervical squamous epithelial cells, with a clear counterstain (HPA: High in cervical squamous epithelial cells; general cytoplasmic expression). | This matches a reported positive tissue and cell type (HPA: tissue IHC). Record the fraction and intensity of stained cells, then compare the pattern with a negative reagent control (standard IHC practice). It does not establish exclusively intracellular localization: COL5A3 is secreted (UniProt P25940 localization). |
| A predominantly nuclear pattern, or staining confined to an unexpected intracellular structure, replaces the reported cytoplasmic tissue pattern (HPA: general cytoplasmic expression). | Treat the compartment mismatch as a possible artefact and review the control slide, antibody concentration, and detection conditions (standard IHC practice). HPA reports plasma membrane localization in ICC-IF, so a membrane outline alone cannot be dismissed across applications (HPA: subcellular ICC-IF). |
| Strong staining appears in adipocytes or lung alveolar cells, both reported as not detected by HPA tissue IHC (HPA: adipose tissue and lung). | Check for cross-reactivity or endogenous detection activity before interpreting those cells as COL5A3 positive (standard IHC practice). HPA's entries refer to those specific cell types; they do not establish that every cell in either tissue is negative (HPA: tissue IHC). |
| Brown signal spreads across the section, including areas without a discernible cell or matrix pattern (standard IHC practice). | Consider nonspecific reagent binding, endogenous detection activity, or inadequate washing (standard IHC practice). Compare negative reagent and known-positive controls, and score localized staining separately from diffuse background (standard IHC practice). |
| No signal is seen in cervical squamous epithelial cells or testicular Leydig cells, both reported High by HPA (HPA: cervix and testis). | First check that the positive control and detection system worked, then review antibody dilution and the validated IHC-P workflow if available (standard IHC practice). A failed stain alone cannot establish absent COL5A3; HPA reports variable tissue staining and pending external verification (HPA: reliability; tissue IHC). |
💡Expected COL5A3 appearanceA credible positive shows discernible cytoplasmic staining in an HPA High cell type, such as cervical squamous epithelium; isolated nuclear staining or uniform brown haze calls for control-based review (HPA: tissue IHC; standard IHC practice).
| Tissue pattern versus protein location | HPA describes general cytoplasmic tissue staining, while UniProt assigns the secreted protein to extracellular space and matrix (HPA: tissue IHC; UniProt P25940 localization). Interpret the observed cell pattern without requiring both sources to describe the same compartment; HPA notes that RNA and protein tissue locations can differ (HPA: reliability). |
| Strength of IHC evidence | The tissue IHC profile is Approved, but antibody staining has low agreement with RNA data and awaits external verification (HPA: reliability). HPA048256 is IHC Approved; the supplied record does not label it Enhanced (HPA: antibodies). Use controls when applying the reported pattern to a new section (standard IHC practice). |
| Processing and epitope | UniProt lists a signal peptide at residues 1–29 and a chain at 30–1745 (UniProt P25940 processing). The supplied sources give no antibody epitope, so they cannot predict whether processing changes staining with the chosen antibody (UniProt P25940 processing; HPA: antibodies). |
| What should IF/ICC show? | HPA reports approved plasma membrane localization in ICC-IF images and lists HPA041695 as ICC Approved (HPA: subcellular ICC-IF; antibodies). The tissue IHC summary instead describes general cytoplasmic expression, with HPA048256 IHC Approved (HPA: tissue IHC; antibodies). Interpret each application against its own evidence. |
| Situation | Likely cause | Next action |
|---|---|---|
| The known-positive section has no staining. | A run-level detection failure or unsuitable working conditions are possible (standard IHC practice). | Check control performance, detection reagents, antibody dilution, and the antibody's validated IHC-P instructions before calling the specimen negative (standard IHC practice; HPA: High in cervical squamous epithelial cells). |
| All tissue compartments show a similar brown haze. | Nonspecific binding, endogenous detection activity, or incomplete washing may obscure a cell-specific pattern (standard IHC practice). | Inspect a negative reagent control, verify blocking and washing, and evaluate the intended cells only after the background is controlled (standard IHC practice). |
| Nuclei stain strongly while cytoplasm is faint. | The distribution conflicts with HPA's general cytoplasmic tissue profile (HPA: tissue IHC). | Compare the positive and negative controls and reassess detection conditions before scoring nuclear signal as COL5A3 (standard IHC practice; HPA: tissue IHC). |
| Unexpected cells stain strongly, including adipocytes. | The result differs from HPA's not-detected adipocyte entry; cross-reactivity or endogenous detection activity is possible (HPA: adipose tissue; standard IHC practice). | Confirm cell identity and compare controls; do not extend HPA's adipocyte result to every cell in adipose tissue (standard IHC practice; HPA: tissue IHC). |
| The IHC and ICC-IF compartment calls differ. | HPA reports cytoplasmic tissue IHC and plasma membrane ICC-IF, with different antibodies approved for the two applications (HPA: tissue IHC; subcellular ICC-IF; antibodies). | Report the application and antibody used, and assess each image against its application-specific HPA pattern (HPA: tissue IHC; subcellular ICC-IF; antibodies). |
| Staining varies between tissue sections. | HPA reports High, Medium, Low, and not-detected observations across specified tissues and cells; its IHC reliability note flags low agreement with RNA data (HPA: tissue IHC; reliability). | Compare the same cell type across sections and include an HPA-reported positive control in the staining run (HPA: tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing COL5A3 staining
A10525 · IHCImmunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using Collagen V alpha3 Antibody. The picture on the right
A10525 · IFImmunofluorescence analysis of HeLa cells, using Collagen V alpha3 Antibody. The picture on the right is blocked with the synthesized peptid
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/cerebral+cortex#imid_14501752
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/colon#imid_14581147
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/liver#imid_14581146
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000080573-COL5A3/tissue/kidney#imid_14581151
HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA041695; green = COL5A3, blue = nucleus, red = microtubules.
HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA041695; green = COL5A3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for COL5A3 IHC & IF
🧪Run cervix first and assess squamous epithelial cells, which HPA scores High; use adipose tissue as the negative comparator and assess adipocytes, which HPA scores Not detected (HPA: cervix squamous epithelial cells; HPA: adipose tissue adipocytes). On the cervix slide, treat morphologically intact cells showing only counterstain and background-level chromogen as internal negatives, without presuming a specific cell type is negative (standard IHC practice).
Positive control tissue: Cervix (Squamous epithelial cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show COL5A3 in ASC52telo, BJ [Human fibroblast], U2OS, with annotated localisation: Plasma membrane (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control and a nonimmune isotype control matched to the primary antibody’s host species, immunoglobulin class, and concentration; use a COL5A3 knockout specimen if available or the peptide-block control shown in the catalog antibody’s tissue-IHC caption (standard IHC practice; A10525 tissue-IHC caption). For cervical chromogenic IHC, quench endogenous peroxidase and check for signal in inflammatory cells; for IF, assess tissue autofluorescence with a no-primary control (standard IHC/IF practice).
⚠️Feasibility: The selected A10525 paraffin-section caption does not report a fixative, so fixation is unconfirmed (A10525 tissue-IHC caption). A target-specific fixation window and retrieval dependence are unreported in the supplied evidence; optimize antigen retrieval empirically for paraffin sections (supplied target/application evidence; standard IHC practice). The evidence does not establish whether frozen sections or IF would be easier; in cervix, distinguish extracellular matrix staining from peroxidase-associated signal in any inflammatory cells (UniProt P25940: extracellular matrix; standard IHC practice). The selected A10525 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image A10525).
HPA tissue IHC evidence for COL5A3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Secreted protein, tissue location of RNA and protein is expected to differ. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | High | Protein (IHC) | HPA → |
| Small intestine | Glandular cells | High | Protein (IHC) | HPA → |
| Testis | Leydig cells | High | Protein (IHC) | HPA → |
| Tonsil | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Not detected | Protein (IHC) | HPA → |
| Lung | Alveolar cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced COL5A3 IHC Tips
Troubleshoot COL5A3 staining in paraffin section IHC by checking retrieval, compartment, controls, and scoring before interpreting chromogenic signal.
How should I retrieve COL5A3 in paraffin sections when staining is weak?
Use citrate buffer at pH 6.0 for heat induced retrieval at 95–98 °C for 20 min (page retrieval setting). Run a small retrieval time series on adjacent sections while keeping antibody concentration and chromogen development constant, then compare signal with section integrity (standard IHC practice). COL5A3 is secreted and associated with extracellular matrix, so inspect both deposited material and nearby cells rather than judging retrieval by cytoplasmic intensity alone (UniProt P25940 localisation). The selected A10525 image shows paraffin section staining with a peptide blocked comparison, but its caption does not report a fixative or establish retrieval performance across specimens (A10525 tissue IHC caption).
Could fixation explain inconsistent COL5A3 staining between paraffin blocks?
Target specific fixation sensitivity for COL5A3 is unknown from the supplied IHC evidence; the A10525 paraffin section caption does not state its fixative (A10525 tissue IHC caption). Record fixative, time before fixation, fixation duration, processing schedule, and block age for each specimen before comparing chromogenic intensity (standard IHC practice). For a controlled comparison, process matched samples consistently and apply the page’s citrate pH 6.0, 95–98 °C, 20 min retrieval to all sections (page retrieval setting). Treat altered staining after a processing change as a workflow observation requiring controls, without assigning a COL5A3 specific fixation effect from tissue patterns or protein structure (standard IHC interpretation).
Should COL5A3 IHC be scored in cells or extracellular matrix?
Examine extracellular deposits and cell associated staining separately because COL5A3 is annotated as secreted into the extracellular matrix (UniProt P25940 localisation). HPA describes general cytoplasmic tissue staining, while its ICC/IF subcellular assessment places the protein at the plasma membrane (HPA tissue IHC profile; HPA subcellular). Mark those compartments explicitly on adjacent sections and compare their distributions with morphology before combining any scores (standard IHC practice). A solely intracellular chromogenic pattern does not by itself establish matrix deposition, and HPA reports low consistency between antibody staining and RNA expression for this secreted protein (UniProt P25940 localisation; HPA tissue IHC reliability description).
How do processing and epitope position affect COL5A3 IHC interpretation?
COL5A3 has a 1–29 signal peptide and an annotated chain spanning residues 30–1745, with no listed isoforms (UniProt P25940 processing; UniProt P25940 isoforms). It also has glycosylation sites at residues 102, 141, and 349, which makes documented epitope location useful when comparing reagents (UniProt P25940 glycosylation; standard IHC interpretation). Confirm the catalog antibody’s stated immunogen or epitope before attributing a staining difference to processing; the supplied caption does not identify that region (A10525 tissue IHC caption). Its synthesized peptide blocked image supports assessment of peptide competitive staining in that paraffin specimen, but does not establish which molecular region remains accessible under every processing condition (A10525 tissue IHC caption; standard IHC interpretation).
How can IF help check an ambiguous COL5A3 chromogenic pattern?
On a separate IF/ICC workflow, pair COL5A3 with a validated marker for the cell population under examination and inspect overlap alongside extracellular distribution (standard IF practice; UniProt P25940 localisation). Choose spectrally separated fluorophores and place the weaker target signal in a channel with low specimen autofluorescence, checking unstained controls first (standard IF practice). Because COL5A3 has no transmembrane segment and is annotated as secreted, start with conditions that preserve surface and extracellular epitopes; add mild permeabilisation only if the antibody’s documented epitope requires intracellular access (UniProt P25940 topology; UniProt P25940 localisation; standard IF practice). HPA reports an approved plasma membrane ICC/IF location, which can guide inspection but does not validate this catalog antibody’s IF performance (HPA subcellular; A10525 tissue IHC caption).
How can I separate COL5A3 signal from chromogenic IHC background?
Compare the test section with a no primary control, a secondary only control where appropriate, and the available peptide blocked A10525 image when assessing stain specificity (standard IHC practice; A10525 tissue IHC caption). Quench endogenous peroxidase before horseradish peroxidase detection, block nonspecific binding, and keep DAB development matched across comparison sections (standard chromogenic IHC practice). Review tissue edges, damaged areas, and diffuse precipitate separately from structured cellular or matrix staining under the same microscope settings (standard IHC interpretation). COL5A3 is secreted into extracellular matrix, so extracellular colour is plausible, but distribution alone cannot exclude trapped reagent or chromogen deposit (UniProt P25940 localisation; standard IHC interpretation).
What should a COL5A3 IHC score measure when compartments differ? ⚠ ANSWER MARKED FOR VERIFICATION
Predefine separate readouts for cell associated and extracellular staining because COL5A3 is secreted, while HPA also describes cytoplasmic tissue staining (UniProt P25940 localisation; HPA tissue IHC profile). For cells, report percentage positive and an H-score based on 0–3 intensity categories; for deposited matrix, report stained area or optical density per mm² of evaluable tissue (standard IHC quantification practice). Normalise cell scores to the relevant counted cell population and matrix measurements to viable tissue area, excluding folds, edges, and necrotic regions by a preset rule (standard IHC quantification practice). Keep retrieval, illumination, threshold, and DAB development consistent, and report compartment scores separately before comparing specimens (page retrieval setting; standard IHC quantification practice).
When is a COL5A3 positive IHC pattern biologically credible?
A credible result has reproducible cell associated or extracellular staining in intact tissue and a weaker matched negative control (UniProt P25940 localisation; standard IHC interpretation). The A10525 paraffin breast carcinoma image includes a synthesized peptide blocked comparison, offering a reagent specific control for that illustrated specimen (A10525 tissue IHC caption). Treat isolated nuclear colour, edge accentuation, necrotic deposits, and staining reproduced by no primary or peroxidase controls as possible artefacts requiring review (UniProt P25940 localisation; standard IHC interpretation). HPA reports high staining in cervix squamous epithelial cells but also low consistency between staining and RNA data, so a tissue label alone should not decide whether an individual section is positive (HPA tissue IHC positive list; HPA tissue IHC reliability description).
Boster reagents
Best COL5A3 / Collagen alpha-3(V) chain IHC Antibodies
A10525 has IHC data from paraffin-embedded human breast carcinoma tissue and IF data from HeLa cells (catalog image captions); its listed reactivity is Human (catalog).
Real IHC data
Anti-Collagen alpha-3(V) chain COL5A3 Antibody
Cat # A10525
A10525 will render with an IHC figure from paraffin-embedded human breast carcinoma tissue, including a peptide-blocked comparison (catalog IHC image caption). Its listed applications include IHC and IF (catalog), and its IF image shows HeLa cells with a peptide-blocked comparison (catalog IF image caption).
Which to pick: For tissue IHC, choose A10525: its IHC image documents paraffin-embedded human breast carcinoma tissue (catalog IHC image caption), with a listed IHC dilution of 1:100–1:300 (catalog); the fixative is unreported (catalog IHC image caption). For IF/ICC, A10525 is the available choice because IF is listed and shown in HeLa cells (catalog applications and IF image caption); it is polyclonal (catalog). There is no cross-species choice in this payload: A10525 lists Human reactivity only (catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P25940 (CO5A3_HUMAN, Collagen alpha-3(V) chain).
- Human Protein Atlas. COL5A3 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. COL5A3 subcellular location (ICC-IF): Localized to the plasma membrane..
- Human Protein Atlas. COL5A3 antibody validation summary (2 antibodies).
- Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes. Journal of immunology research 2022 — PMC9018183.
- Systematic establishment and verification of an epithelial-mesenchymal transition gene signature for predicting prognosis of oral squamous cell carcinoma. Frontiers in genetics 2023 — PMC10447895.
- Identifying endoplasmic reticulum stress-related genes as new diagnostic and prognostic biomarkers in clear cell renal cell carcinoma. Translational andrology and urology 2024 — PMC10891384.
- PubMed PMID:10722718 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
- PubMed PMID:1571108 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for COL5A3 (Collagen alpha-3(V) chain). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); extracellular matrix expected (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10525 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Cervix (Squamous epithelial cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A10525); 2. Fixation: Image fixative and duration unreported (datasheet A10525); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-COL5A3, 1:100-1:300 (datasheet A10525); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A10525); Caveat: Secreted protein; tissue staining may diverge from RNA (HPA tissue IHC); Isoform / epitope: No isoforms; signal 1–29 is removed; no cytoplasmic epitope (UniProt); Regulation: Regulation not specified (UniProt). Evidence: UniProt P25940, HPA tissue IHC · Approved, HPA ICC-IF · plasma membrane., Datasheet A10525, PMC10891384. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/COL5A3/immunohistochemistry-ihc-guide.